Écologie saisonnière des parasitoïdes des oeufs de l'arpenteuse de la pruche

Cette étude porte sur l’écologie saisonnière des parasitoïdes des œufs de l’arpenteuse de la pruche (Lepidoptera : Geometridae), un important défoliateur du Québec (Canada). Premièrement, nous décrivons les patrons saisonniers de parasitisme d’hôtes sentinelles par Telenomus coloradensis, T. droozi, T. flavotibiae (Hymenoptera : Scelionidae), et Trichogramma spp., dans la région du Bas-Saint-Laurent. Telenomus flavotibiae et Trichogramma spp. parasitent rarement les œufs de l’arpenteuse de la pruche alors que T. coloradensis et T. droozi sont très abondants au printemps. En laboratoire, la convenance des hôtes pour T. coloradensis diminue rapidement avec leur développement embryonnaire au printemps, affectant négativement les niveaux de parasitisme, ainsi que la survie, la taille, le temps de développement et la longévité de la progéniture. Telenomus coloradensis et T. droozi sont actifs très tôt en saison, alors que les températures sont froides (4°C) pour profiter du développement embryonnaire peu avancé de l’hôte. À partir de paramètres empiriques, nous estimons que la progéniture de T. coloradensis issue du parasitisme printanier émerge au milieu de l’été, alors que l’hôte est totalement absent de l’environnement forestier. La nouvelle génération de femelles serait donc susceptible d’entrer précocement en diapause reproductive. D’ailleurs, nos résultats de laboratoire démontrent qu’une période de privation d’hôtes affecte négativement l’activité parasitaire de T. coloradensis. Ce phénomène pourrait expliquer les niveaux très faibles de parasitisme des œufs de l’arpenteuse de la pruche à l’automne. Étonnamment toutefois, les hôtes en début de diapause (à l’automne) sont de meilleure qualité énergétique que les hôtes en post-diapause (au printemps). Alors que des études précédentes ont démontré que T. coloradensis peut survivre à l’hiver en tant qu’immature à l’intérieur des hôtes, nos résultats indiquent que ce sont principalement les femelles fertilisés qui passent l’hiver en diapause reproductive, avec un point de surfusion automnal moyen de -30,6°C.This study focuses on the seasonal ecology of egg parasitoids of the hemlock looper (Lepidoptera: Geometridae), a major forest defoliator in the province of Quebec (Canada). At first, we describe the seasonal occurrence of parasitism in sentinel hosts by Telenomus coloradensis, T. droozi, T. flavotibiae (Hymenoptera: Scelionidae) and Trichogramma spp., in the Lower St.Lawrence region. Telenomus flavotibiae and Trichogramma spp. rarely parasitize eggs of the hemlock looper, while T. coloradensis and T. droozi are very abundant in spring. In the laboratory, the host suitability for T. coloradensis decreases rapidly with their embryonic development in spring, affecting negatively the levels of parasitism, as well as the survival, size, development time and longevity of offspring. Accordingly, female T. coloradensis and T. droozi are active very early in season, when temperature is cold (4° C), presumably to benefit from low embryonic development of the host. From developmental parameters measured in the laboratory, we estimate that the spring progeny of T. coloradensis emerges in mid-summer, when eggs of the hemlock looper are totally absent from the forest environment. The new generation of female parasitoids is thus expected to enter in a early reproductive diapause : our laboratory results show that an extended host deprivation period negatively affects parasitism by T. coloradensis. This may contribute to explain the very low levels of parasitism of hemlock looper eggs in fall. Our laboratory tests also show that unfertilized eggs in the fall do not allow the development of T. coloradensis. Surprisingly, however, host eggs in early-diapause (in autumn) are energically more suitable than hosts in post-diapause (in spring). While previous studies have shown that T. coloradensis may overwinter as immature eggs inside the host, our field and laboratory results indicate that it is mainly the fertilized females of this species that overwinter in reproductive diapause, with a supercooling point of -30.6 °C in fall

Perceptions of U.S. and Canadian maple syrup producers toward climate change, its impacts, and potential adaptation measures

The production of maple syrup is an important cultural and economic activity directly related to the climate of northeastern North America. As a result, there are signs that climate change could have negative impacts on maple syrup production in the next decades, particularly for regions located at the southern margins of the sugar maple (Acer saccharum Marsh.) range. The purpose of this survey study is to present the beliefs and opinions of maple syrup producers of Canada (N = 241) and the U.S. (N = 113) on climate change in general, its impacts on sugar maple health and maple syrup production, and potential adaptation measures. Using conditional inference classification trees, we examined how the socio-economic profile of respondents and the geographic location and size of respondents’ sugar bushes shaped the responses of survey participants. While a majority (75%) of respondents are confident that the average temperature on Earth is increasing, less than half (46%) believe that climate change will have negative impacts on maple syrup yield in the next 30 years. Political view was a significant predictor of these results, with respondents at the right right and center-right of the political spectrum being less likely to believe in climate change and less likely to anticipate negative effects of climate change on maple syrup production. In addition, 77% of the participants indicated an interest in adopting adaptation strategies if those could increase maple syrup production. This interest was greater for respondents using vacuum tubing for sap collection than other collection methods. However, for many respondents (particularly in Canada), lack of information was identified as a constraint limiting adaptation to climate change.SL and AP were partly funded by the CICan Career-Launcher Internship program. AA was supported by Spanish Government through the Juan de la Cierva fellowship program (IJCI- 2016-30049)

Avionics graphics hardware performance prediction with machine learning

Within the strongly regulated avionic engineering field, conventional graphical desktop hardware and software application programming interface (API) cannot be used because they do not conform to the avionic certification standards. We observe the need for better avionic graphical hardware, but system engineers lack system design tools related to graphical hardware. The endorsement of an optimal hardware architecture by estimating the performance of a graphical software, when a stable rendering engine does not yet exist, represents a major challenge. As proven by previous hardware emulation tools, there is also a potential for development cost reduction, by enabling developers to have a first estimation of the performance of its graphical engine early in the development cycle. In this paper, we propose to replace expensive development platforms by predictive software running on a desktop computer. More precisely, we present a system design tool that helps predict the rendering performance of graphical hardware based on the OpenGL Safety Critical API. First, we create nonparametric models of the underlying hardware, with machine learning, by analyzing the instantaneous frames per second (FPS) of the rendering of a synthetic 3D scene and by drawing multiple times with various characteristics that are typically found in synthetic vision applications. The number of characteristic combinations used during this supervised training phase is a subset of all possible combinations, but performance predictions can be arbitrarily extrapolated. To validate our models, we render an industrial scene with characteristic combinations not used during the training phase and we compare the predictions to those real values. We find a median prediction error of less than 4 FPS

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

<p>Abstract</p> <p>Background</p> <p>It has been shown in in-vitro experiments that "withdrawal" of tamoxifen inhibits growth of tumor cells. However, evidence is scarce when this is extrapolated into clinical context. We report our experience to verify the clinical relevance of "withdrawal therapy".</p> <p>Methods</p> <p>Breast cancer patients since 1998 who fulfilled the following criteria were selected from the departmental database and the case-notes were retrospectively reviewed: (1) estrogen receptor positive, operable primary breast cancer in elderly (age > 70 years), locally advanced or metastatic breast cancer; (2) disease deemed suitable for treatment by hormonal manipulation; (3) disease assessable by UICC criteria; (4) received "withdrawal" from a prior endocrine agent as a form of therapy; (5) on "withdrawal therapy" for ≥ 6 months unless they progressed prior.</p> <p>Results</p> <p>Seventeen patients with median age of 84.3 (53.7-92.5) had "withdrawal therapy" as second to tenth line of treatment following prior endocrine therapy using tamoxifen (n = 10), an aromatase inhibitor (n = 5), megestrol acetate (n = 1) or fulvestrant (n = 1). Ten patients (58.8%) had clinical benefit (CB) (complete response/partial response/stable disease ≥ 6 months) with a median duration of Clinical Benefit (DoCB) of 10+ (7-27) months. Two patients remain on "withdrawal therapy" at the time of analysis.</p> <p>Conclusion</p> <p>"Withdrawal therapy" appears to produce sustained CB in a significant proportion of patients. This applies not only to "withdrawal" from tamoxifen, but also from other categories of endocrine agents. "Withdrawal" from endocrine therapy is, therefore, a viable intercalating option between endocrine agents to minimise resistance and provide additional line of therapy. It should be considered as part of the sequencing of endocrine therapy.</p

Paternal age explains a major portion of de novo germline mutation rate variability in healthy individuals

De novo mutations (DNM) are an important source of rare variants and are increasingly being linked to the development of many diseases. Recently, the paternal age effect has been the focus of a number of studies that attempt to explain the observation that increasing paternal age increases the risk for a number of diseases. Using disease-free familial quartets we show that there is a strong positive correlation between paternal age and germline DNM in healthy subjects. We also observed that germline CNVs do not follow the same trend, suggesting a different mechanism. Finally, we observed that DNM were not evenly distributed across the genome, which adds support to the existence of DNM hotspots

Pharmacogenomics of the efficacy and safety of Colchicine in COLCOT

© 2021 The Authors. Circulation: Genomic and Precision Medicine is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.Background: The randomized, placebo-controlled COLCOT (Colchicine Cardiovascular Outcomes Trial) has shown the benefits of colchicine 0.5 mg daily to lower the rate of ischemic cardiovascular events in patients with a recent myocardial infarction. Here, we conducted a post hoc pharmacogenomic study of COLCOT with the aim to identify genetic predictors of the efficacy and safety of treatment with colchicine. Methods: There were 1522 participants of European ancestry from the COLCOT trial available for the pharmacogenomic study of COLCOT trial. The pharmacogenomic study's primary cardiovascular end point was defined as for the main trial, as time to first occurrence of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina requiring coronary revascularization. The safety end point was time to the first report of gastrointestinal events. Patients' DNA was genotyped using the Illumina Global Screening array followed by imputation. We performed a genome-wide association study in colchicine-treated patients. Results: None of the genetic variants passed the genome-wide association study significance threshold for the primary cardiovascular end point conducted in 702 patients in the colchicine arm who were compliant to medication. The genome-wide association study for gastrointestinal events was conducted in all 767 patients in the colchicine arm and found 2 significant association signals, one with lead variant rs6916345 (hazard ratio, 1.89 [95% CI, 1.52-2.35], P=7.41×10-9) in a locus which colocalizes with Crohn disease, and one with lead variant rs74795203 (hazard ratio, 2.51 [95% CI, 1.82-3.47]; P=2.70×10-8), an intronic variant in gene SEPHS1. The interaction terms between the genetic variants and treatment with colchicine versus placebo were significant. Conclusions: We found 2 genomic regions associated with gastrointestinal events in patients treated with colchicine. Those findings will benefit from replication to confirm that some patients may have genetic predispositions to lower tolerability of treatment with colchicine.info:eu-repo/semantics/publishedVersio

Movement of the human foot in 100 pain free individuals aged 18–45 : implications for understanding normal foot function

Background: Understanding motion in the normal healthy foot is a prerequisite for understanding the effects of pathology and thereafter setting targets for interventions. Quality foot kinematic data from healthy feet will also assist the development of high quality and research based clinical models of foot biomechanics. To address gaps in the current literature we aimed to describe 3D foot kinematics using a 5 segment foot model in a population of 100 pain free individuals. Methods: Kinematics of the leg, calcaneus, midfoot, medial and lateral forefoot and hallux were measured in 100 self reported healthy and pain free individuals during walking. Descriptive statistics were used to characterise foot movements. Contributions from different foot segments to the total motion in each plane were also derived to explore functional roles of different parts of the foot. Results: Foot segments demonstrated greatest motion in the sagittal plane, but large ranges of movement in all planes. All foot segments demonstrated movement throughout gait, though least motion was observed between the midfoot and calcaneus. There was inconsistent evidence of movement coupling between joints. There were clear differences in motion data compared to foot segment models reported in the literature. Conclusions: The data reveal the foot is a multiarticular structure, movements are complex, show incomplete evidence of coupling, and vary person to person. The data provide a useful reference data set against which future experimental data can be compared and may provide the basis for conceptual models of foot function based on data rather than anecdotal observations

Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination

Objective Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality. Methods We used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis. Results Ninety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p < 0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR = 0.19, 95% CI = 0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR = 0.70, 95% CI = 0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR = 2.19, 95% CI = 0.74-6.54). Conclusions In patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL 2022Peer reviewe

Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19

Introduction: Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease with high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the differences in presentation, treatment, clinical course, complications, and outcome of CVST-VITT between women and men. Patients and methods: We used data from an ongoing international registry on CVST-VITT. VITT was diagnosed according to the Pavord criteria. We compared the characteristics of CVST-VITT in women and men. Results: Of 133 patients with possible, probable, or definite CVST-VITT, 102 (77%) were women. Women were slightly younger [median age 42 (IQR 28–54) vs 45 (28–56)], presented more often with coma (26% vs 10%) and had a lower platelet count at presentation [median (IQR) 50x109/L (28–79) vs 68 (30–125)] than men. The nadir platelet count was lower in women [median (IQR) 34 (19–62) vs 53 (20–92)]. More women received endovascular treatment than men (15% vs 6%). Rates of treatment with intravenous immunoglobulins were similar (63% vs 66%), as were new venous thromboembolic events (14% vs 14%) and major bleeding complications (30% vs 20%). Rates of good functional outcome (modified Rankin Scale 0-2, 42% vs 45%) and in-hospital death (39% vs 41%) did not differ. Discussion and conclusions: Three quarters of CVST-VITT patients in this study were women. Women were more severely affected at presentation, but clinical course and outcome did not differ between women and men. VITT-specific treatments were overall similar, but more women received endovascular treatment.</p